According to a Bristol Myers Squibb spokesperson, the wholesale cost for a month's supply will be $1,850. Depending on people's insurance coverage, that cost could be lower for individual patients. Bristol Myers Squibb estimates that 80% of people with schizophrenia in the U.S. have insurance coverage either through Medicare or Medicaid.So, schizo's are mostly geezers and/or in shithole circumstances? Is that what Bristol thinks/hopes? What would MAGA do?
And, for what it's worth, I'm still not clear that such would be covered by M/M directly, since this is not a doctor's office drug. It would be 'covered' for those who pay for Part D, which isn't always cheap. And United Health, et al, have built up a deserved reputation of putting profit before patient; will Cobenfy be as cheap as generic SoC? Not likely. So, it's really not Socialized Medicine, as generally defined. Who wooda thunk it?
No comments:
Post a Comment